GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-16. Numbers and descriptions here follow the published literature rather than marketing material.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
== History == The application for imipenem/cilastatin/relebactam was granted Qualified Infectious Disease Product (QIDP), fast track, and priority review designations by the U.S. Food and Drug Administration (FDA). The FDA granted the approval of Recarbrio to Merck & Co., Inc. The determination of efficacy of imipenem/cilastatin/relebactam was supported in part by the findings of the efficacy and safety of imipenem-cilastatin for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). The contribution of relebactam to imipenem/cilastatin/relebactam was assessed based on data from in vitro studies and animal models of infection. The safety of imipenem/cilastatin/relebactam, administered via injection, was studied in two trials (Trial 1/NCT01505634, Trial 2/NCT01506271), one each for cUTI and cIAI. The cUTI trial included 298 adult participants with 99 treated with the proposed dose of imipenem/cilastatin/relebactam. The cIAI trial included 347 participants with 117 treated with the proposed dose of imipenem/cilastatin/relebactam. Trial 1 enrolled adult participants hospitalized with cUTI. Trial 2 enrolled adult participants hospitalized with cIAI that required surgery or drainage. In both trials, participants were assigned to either imipenem/cilastatin with varying doses of relebactam or imipenem/cilastatin with placebo intravenously, every 6 hours for 4 to 14 days. Neither the participants nor the investigators knew which treatment was being given until after the trial was completed.
Dating back to Anaxagoras in the 5th century BC, panspermia is the idea that life originated elsewhere in the universe and came to Earth. The modern version of panspermia holds that life may have been distributed to Earth by meteoroids, asteroids, comets or planetoids. This shifts the origin of life to another heavenly body. The advantage is that life is not required to have formed on each planet it occurs on, but in a more limited set of locations, and then spread about the galaxy to other star systems. There is some interest in the possibility that life originated on Mars and later transferred to Earth.
== Epidemiology == Cardiovascular disease, which is predominantly the clinical manifestation of atherosclerosis, is one of the leading causes of death worldwide. Almost all children older than age 10 in developed countries have aortic fatty streaks, with coronary fatty streaks beginning in adolescence. In 1953, a study was published that examined the results of 300 autopsies performed on U.S. soldiers who had died in the Korean War. Despite the average age of the soldiers being just 22 years old, 77% of them had visible signs of coronary atherosclerosis. This study showed that heart disease could affect people at a younger age and was not just a problem for older individuals. In 1992, a report showed that microscopic fatty streaks were found in the left anterior descending artery in over 50% of children aged 10–14, and 8% had even more advanced lesions with more accumulations of extracellular lipid. A 2005 report of a study from 1985 to 1995 found that around 87% of aortas and 30% of coronary arteries in the age group 5–14 years had fatty streaks, which increased with age.
Sources: en.wikipedia.org
==== Cumaná ==== On the morning of July 16, 1799, the Pizarro anchored at Cumana, and even those weakened by typhus managed to witness their arrival. Humboldt, eager to immerse himself in the new environment, immediately visited the home of their native guide, disregarding the captain's reminder about the need to present credentials to the Governor first. In the shade of a mimosa tree, surrounded by unfamiliar tropical fragrances and the daily life of their host’s family, Humboldt found the experience more rewarding than any official audience could provide. The town of Cumana, or what remained of it after a devastating earthquake, presented a scene of partial ruin. Governor Don Vicente Emparán, a progressive and scientifically minded official, welcomed the explorers warmly. As head of New Andalusia, then part of the Spanish colony of New Granada, Emparán took pride in introducing Humboldt and Bonpland to local crafts, especially textiles and furniture made from native materials. His appreciation for science ensured that Humboldt and Bonpland received favorable treatment during their South American travels. The natural scenery, with its mist-shrouded mountains, vibrant birds, and luxuriant plant life, left Humboldt and Bonpland exhilarated and overwhelmed by the proliferation of unfamiliar sights, sounds, and smells. The explorers quickly secured a spacious house constructed of local woods, cooled by the breeze through open windows.
== Intestinal macrophages == Though very similar in structure to tissue macrophages, intestinal macrophages have evolved specific characteristics and functions given their natural environment, which is in the digestive tract. Macrophages and intestinal macrophages have high plasticity causing their phenotype to be altered by their environments. Like macrophages, intestinal macrophages are differentiated monocytes, though intestinal macrophages have to coexist with the microbiome in the intestines. This is a challenge considering the bacteria found in the gut are not recognized as "self" and could be potential targets for phagocytosis by the macrophage. To prevent the destruction of the gut bacteria, intestinal macrophages have developed key differences compared to other macrophages. Primarily, intestinal macrophages do not induce inflammatory responses. Whereas tissue macrophages release various inflammatory cytokines, such as IL-1, IL-6 and TNF-α, intestinal macrophages do not produce or secrete inflammatory cytokines. This change is directly caused by the intestinal macrophages environment. Surrounding intestinal epithelial cells release TGF-β, which induces the change from proinflammatory macrophage to noninflammatory macrophage. Even though the inflammatory response is downregulated in intestinal macrophages, phagocytosis is still carried out. There is no drop off in phagocytosis efficiency as intestinal macrophages are able to effectively phagocytize the bacteria,S. typhimurium and E.
Insulin: promotes lipid synthesis, inhibiting lipid breakdown, and facilitating glucose transport and conversion into fatty acids. Glucagon: stimulates fatty acid oxidation and inhibits de novo fatty acid synthesis, reducing VLDL release and hepatic steatosis. Thyroid Hormone: promotes hepatic triglyceride synthesis, enhancing lipolysis, stimulating mitochondrial fatty acid β-oxidation, and regulating cholesterol levels through various mechanisms, including LDL receptor expression and bile acid excretion. Sex Hormone: Estrogen: decreases triglyceride synthesis and enhances HDL cholesterol levels, potentially through promoting fatty acid oxidation and inhibiting lipogenesis. Testosterone: stimulates de novo lipogenesis and fat accumulation which are then incorporated to triglycerides for energy storage. Adrenaline: stimulates lipolysis and inhibits lipogenesis via AMPK phosphorylation, influencing lipid turnover and accumulation in adipose tissue.
Sources: en.wikipedia.org
== Current status == PeptideAtlas is still maintained and developed at the Institute for Systems Biology in the research lab of Robert Moritz, led by Eric Deutsch, and with significant efforts by Zhi Sun and Dave Campbell.
== See also == Category:Cutaneous conditions Dermatology List of conditions associated with café au lait macules List of contact allergens List of cutaneous conditions associated with increased risk of nonmelanoma skin cancer List of cutaneous conditions associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms associated with systemic syndromes List of cutaneous conditions caused by problems with junctional proteins List of dental abnormalities associated with cutaneous conditions List of genes mutated in cutaneous conditions List of genes mutated in pigmented cutaneous lesions List of histologic stains that aid in diagnosis of cutaneous conditions List of human leukocyte antigen alleles associated with cutaneous conditions List of immunofluorescence findings for autoimmune bullous conditions List of inclusion bodies that aid in diagnosis of cutaneous conditions List of keratins expressed in the human integumentary system List of migrating cutaneous conditions List of mites associated with cutaneous reactions List of radiographic findings associated with cutaneous conditions List of specialized glands within the human integumentary system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in pemphigus List of verrucous carcinoma subtypes List of xanthoma variants associated with hyperlipoproteinemia subtypes
=== Synthesis === The chemical synthesis of MDMA has been described. There are numerous methods available to synthesize MDMA via different intermediates. The original MDMA synthesis described in Merck's patent involves brominating safrole to 1-(3,4-methylenedioxyphenyl)-2-bromopropane and then reacting this adduct with methylamine. Most illicit MDMA is synthesized using MDP2P (3,4-methylenedioxyphenyl-2-propanone) as a precursor. MDP2P in turn is generally synthesized from piperonal, safrole or isosafrole. One method is to isomerize safrole to isosafrole in the presence of a strong base, and then oxidize isosafrole to MDP2P. Another method uses the Wacker process to oxidize safrole directly to the MDP2P intermediate with a palladium catalyst. Once the MDP2P intermediate has been prepared, a reductive amination leads to racemic MDMA (an equal parts mixture of (R)-MDMA and (S)-MDMA). Relatively small quantities of essential oil are required to make large amounts of MDMA. The essential oil of Ocotea cymbarum, for example, typically contains between 80 and 94% safrole. This allows 500 mL of the oil to produce between 150 and 340 grams of MDMA.
=== Biosynthesis === The formation of desmosines occurs within the formation of precursor tropoelastin. The tropoelastin initially lacks any of these complex binding molecules, and has a similar make up to that of the final stage elastin, however it contains a greater amount of lysine side chains, which directly corresponds with desmosines later found. These precursor molecules are processed through Dehydrogenation, along with dihydroD, and ultimately form elastin bound with desmosine. Through the Lysyl oxidase enzyme, lysyl c- amino groups is oxidized, forming allysine. This spontaneously condenses with other allysine molecules to form a bifunctional cross-link, allysine aldol, or with a c-amino group of lysine, forming dehydrolysinonorleucine. These compounds are then further condensed to form a tetrafunctional pyridinium cross-links of desmosines and isodesmosines. These reactions occur with lysines in areas of high alanine, due to alanine having a small side chain that won't block the enzyme binding to the lysine groups.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.